Fourth Annual Oncology Health Outcomes & Market Access
Conference - Vienna, Austria
This event will uniquely look at how to generate quality evidence and demonstrate value to global payers, health technology assessors and other key stakeholders for higher-cost oncology therapeutics. Such drugs may include niche cancer biologics, expensive oncology small molecules, orphan drugs, personalized medicines or biosimilars.
This event will look at overcoming the challenge to generate strong evidence to demonstrate value, the latest innovative market access techniques specific to oncology, satisfying HTA requirements to build the right dossier. The discussion will focus on the major elements which affect market and patient access in key markets: pay-for-performance schemes are being constantly reviewed as well as coverage with evidence development and there are still significant implementation barriers.
(Courtesy of Oncology therapeutic experience, via bioduro.com)
http://springpharmaccess2013.nextlevelpharma.com/request-agenda
Mon, May 06, 2013 - Wed, May 08, 2013
Vienna, Austria
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.